No Data
No Data
EVEREST MED-B: 2024 Interim Report
Hong Kong stocks soared in the afternoon. Genting New Vision-B (01952) rose more than 5%, while E Jiahe's sales of Nai Fuke soared significantly, with product sales in the first half of the year increasing by more than 1.5 times compared to the previous p
Yunding Xinyao-B (01952) rose more than 5% in the afternoon, as of the time of writing, up 5.80%, at HKD 21.9, with a turnover of HKD 67.6309 million.
Analysts Have Made A Financial Statement On Everest Medicines Limited's (HKG:1952) Half-Yearly Report
[Brokerage Focus] Bocom Intl raises target price by 7.32% for Genting New York (01952) as YiJiaHe and NaiFuKang sales volume significantly exceeds expectations.
Kingwu Financial News | Bocom Intl released its research report, indicating that the sales performance of Cloud Glory New Shine (01952) in 1H24 was excellent: product sales increased by 158% to 0.302 billion yuan compared to the previous period, exceeding market expectations. This includes: 1) After Nafucan was commercialized in mainland China in May, sales reached 0.167 billion yuan in a month and a half. The NMPA has accepted the supplementary application for full product approval, expected to be approved in 1H25. Future sales growth will mainly come from the promotion and education of guidelines, and possible negotiations for medical insurance access; 2) Yijia sales amounted to 0.134 billion yuan (a 35% increase from 2H23), with subsequent growth prospects being the main focus.
Genting Xinyao-B (01952): The value of scale commercialization is validated again, and the dual-wheel drive continues to boost the value curve.
On August 27th, the mid-year financial results (2024) of Genting Xin Yao-B (01952) were just released. According to the financial report, the company's current revenue reached 0.302 billion yuan (RMB, the same unit), a significant year-on-year increase of 3289.74%.
Genting New Star (01952) widened its interim loss to 0.632 billion RMB and did not pay dividends.
Jingu Financial News | Genting Xinyao (01952) announced that for the six months ended June 30, 2024, the company's equity holders recorded a loss attributable to the period of 6.32 billion yuan (RMB, the same below), a year-on-year increase of 49.29%. This is mainly due to the one-time, non-recurring impairment loss of intangible assets related to the mRNACOVID-19 vaccine. The basic loss per share was 1.97 yuan, and no dividend was declared. During the period, revenue was recorded at 3.02 billion yuan, a year-on-year increase of 3289.74%, mainly due to the continuous expansion of sales by Yijia in mainland China and Hong Kong, and the listing of Naifukang in mainland China and Singapore.
No Data
No Data